Thrombotic Microangiopathy Five Weeks After a Living-Donor Kidney
A textbook drug-toxicity picture, appearing at the textbook moment, is still not the same thing as a confirmed diagnosis — and treating the calcineurin inhibitor as the whole story risks missing a complement-mediated process no amount of drug withdrawal will fix.
Wendy K. is fifty-one, five weeks past a living-donor transplant from a family friend who had offered the kidney the week Wendy's own function crossed into dialysis range from IgA nephropathy diagnosed a decade earlier. Recovery had gone smoothly enough that she was already back to walking her neighborhood's steepest hill without stopping, until this week's routine labs came back wrong in a pattern nobody wanted to see: platelets down to 68,000 from a post-transplant baseline near 220,000, creatinine risen from 1.1 to 1.9, and a smear showing schistocytes — fragmented red cells, the visual signature of red cells being sheared apart somewhere in her circulation rather than simply destroyed.
Her LDH is more than twice the upper limit of normal, and her haptoglobin is unmeasurably low — together with the schistocytes, a hemolytic process, not just a platelet problem in isolation. Her tacrolimus trough has held steady in the low-therapeutic range the entire time, no missed doses, no new interacting drug added, nothing else new in her chart this week except the lab values themselves. That temporal cleanliness is exactly what makes calcineurin-inhibitor toxicity the leading explanation and, at the same time, exactly the kind of clean story worth being suspicious of — a drug-toxicity diagnosis this textbook is also the diagnosis a genuine complement-mediated process would be easiest to hide behind if nobody looks past it.
She has no personal or family history of anything resembling this before — no childhood hemolytic episode, no relative with unexplained kidney failure, nothing her own nephrologist had flagged as worth a baseline complement workup before transplant, since nothing about her IgA nephropathy history would have prompted one. That absence cuts both ways: it makes drug toxicity the more probable single explanation on prior odds alone, and it also means nobody has actually looked for a complement abnormality that a transplant, as a real physiologic stressor in its own right, is a recognized trigger for unmasking in a person who carries one silently.
Inpatient consult, new TMA post-transplant
I'd stop the tacrolimus outright and convert her regimen today. Calcineurin-inhibitor toxicity is a well-established, direct cause of drug-toxicity TMA. I'll be honest about the grade of that evidence up front: there has never been a randomized comparison of withdrawal against reduction, so what we have is retrospective series consistently describing resolution once the drug is actually removed rather than merely reduced. Her picture fits that pattern precisely — steady in-range troughs, no other new exposure, onset exactly where the literature says to expect it.
Five weeks is still inside the highest-risk window for acute cellular rejection, and a full discontinuation on a first for-cause finding gives up a real, working immunosuppressant on a presumptive diagnosis rather than a proven one. I'd rather substantially reduce the dose and monitor daily labs closely — if the platelet count and creatinine start reversing within forty-eight to seventy-two hours, that's the same causal answer with a smaller, more reversible step, and if they don't, we haven't lost the option of stopping it entirely a few days later.
I'm not arguing the drug isn't the likely cause — I agree the pattern fits. I'm arguing we don't need to remove it entirely to test that hypothesis, when a real rejection risk sits on the other side of removing it too fast.
Whatever we decide about the tacrolimus, I don't think either plan actually answers the question that matters most: is this drug toxicity alone, or has the transplant unmasked a complement- mediated process that a CNI dose change, up or down, won't reliably fix? The lab picture in front of us — thrombocytopenia, schistocytes, rising creatinine, elevated LDH — looks identical whether the driver is the drug or dysregulated complement activation; nothing here distinguishes them.
Noris and Remuzzi's account of atypical HUS is why I won't let this rest on clinical pattern alone — the syndrome is defined by complement regulatory-protein variants that stay silent until something stresses the system, and a transplant is precisely such a stressor. And if it is that, Legendre's eculizumab trial is the reason the answer changes completely. I'd send ADAMTS13 activity to rule out TTP, and start a complement workup — CH50, complement factor levels, and genetic testing for the regulatory-protein variants associated with atypical HUS — in parallel with whatever tacrolimus decision is made tonight, not after it. If that workup comes back complement-positive, eculizumab becomes a real consideration regardless of which CNI strategy is chosen, and I'd rather have that answer in hand before her platelet count falls further than wait to see whether the drug change alone was enough.
Agreed: tacrolimus reduced by roughly half rather than stopped outright, daily labs to track response, and a full ADAMTS13/complement workup sent in parallel rather than sequentially. The hematologist's framing — that the CNI decision and the complement question are separate and both urgent — was accepted by both other voices as the correct structure for tonight's plan.
Drug-toxicity TMA treated as confirmed by response; tacrolimus held at the reduced dose or converted off entirely depending on the complement workup result.
Full tacrolimus discontinuation and conversion to a non-CNI regimen; eculizumab started if the complement workup is positive or turnaround is too slow to wait for.
Not agreed: how long to wait for the complement workup's turnaround before acting on clinical grounds alone. The hematologist wants results in hand before any final regimen decision; the transplant physician is not willing to let a graft-threatening process run its full course while a send-out genetic panel is pending, and would act on the 48-72 hour lab trend regardless of whether the complement result has returned by then.